Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Candidiasis, Invasive | 2 | 2017 | 107 | 0.79 | Why? |
| Tendons | 1 | 2019 | 43 | 0.78 | Why? |
| Fosfomycin | 1 | 2018 | 48 | 0.73 | Why? |
| Antifungal Agents | 3 | 2017 | 1828 | 0.71 | Why? |
| Geotrichosis | 1 | 2016 | 3 | 0.69 | Why? |
| Geotrichum | 1 | 2016 | 3 | 0.69 | Why? |
| Staphylococcal Skin Infections | 1 | 2017 | 32 | 0.68 | Why? |
| Leptospirosis | 1 | 2018 | 103 | 0.65 | Why? |
| Gastrostomy | 1 | 2016 | 56 | 0.65 | Why? |
| Bone and Bones | 1 | 2019 | 235 | 0.64 | Why? |
| Dermatomycoses | 1 | 2016 | 55 | 0.63 | Why? |
| Anti-Infective Agents | 2 | 2018 | 1766 | 0.61 | Why? |
| Cellulitis | 1 | 2016 | 119 | 0.60 | Why? |
| Soft Tissue Infections | 1 | 2017 | 116 | 0.60 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.59 | Why? |
| Allografts | 1 | 2019 | 761 | 0.58 | Why? |
| Hospital Administration | 1 | 2021 | 650 | 0.54 | Why? |
| Diagnostic Errors | 1 | 2018 | 865 | 0.44 | Why? |
| Surgical Wound Infection | 1 | 2016 | 501 | 0.44 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.41 | Why? |
| Anti-Bacterial Agents | 7 | 2018 | 10083 | 0.40 | Why? |
| Bacteria | 1 | 2019 | 1897 | 0.35 | Why? |
| Consensus | 3 | 2020 | 6345 | 0.33 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.33 | Why? |
| Sepsis | 3 | 2018 | 3517 | 0.32 | Why? |
| Workplace | 1 | 2018 | 2075 | 0.29 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.28 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.27 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.25 | Why? |
| Surgical Procedures, Operative | 1 | 2019 | 2662 | 0.25 | Why? |
| Occupational Diseases | 1 | 2018 | 2787 | 0.24 | Why? |
| Stenotrophomonas maltophilia | 1 | 2002 | 63 | 0.24 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.22 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.21 | Why? |
| Bacterial Infections | 4 | 2018 | 2229 | 0.21 | Why? |
| Gross Domestic Product | 1 | 2021 | 134 | 0.20 | Why? |
| HTLV-I Infections | 1 | 2019 | 54 | 0.19 | Why? |
| Occupational Exposure | 1 | 2018 | 4742 | 0.19 | Why? |
| Pharmaceutical Research | 1 | 2018 | 34 | 0.18 | Why? |
| Sanitary Engineering | 1 | 2018 | 20 | 0.18 | Why? |
| Spain | 4 | 2021 | 15545 | 0.18 | Why? |
| Pneumocystis carinii | 1 | 2020 | 205 | 0.18 | Why? |
| Models, Economic | 1 | 2021 | 316 | 0.18 | Why? |
| Magnesium Oxide | 1 | 2016 | 3 | 0.17 | Why? |
| Flucytosine | 1 | 2016 | 12 | 0.17 | Why? |
| Endocarditis, Bacterial | 1 | 2002 | 344 | 0.17 | Why? |
| Pharyngeal Diseases | 1 | 2017 | 56 | 0.17 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2002 | 398 | 0.17 | Why? |
| Biomarkers | 3 | 2017 | 23361 | 0.17 | Why? |
| Emergency Service, Hospital | 4 | 2021 | 14232 | 0.17 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.16 | Why? |
| Echinocandins | 1 | 2017 | 139 | 0.16 | Why? |
| Linezolid | 1 | 2017 | 160 | 0.15 | Why? |
| Pneumonia, Pneumocystis | 1 | 2020 | 322 | 0.15 | Why? |
| Amphotericin B | 1 | 2016 | 256 | 0.15 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.14 | Why? |
| Mouth Diseases | 1 | 2017 | 193 | 0.14 | Why? |
| Demography | 1 | 2021 | 1660 | 0.13 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.13 | Why? |
| Candidemia | 1 | 2017 | 353 | 0.12 | Why? |
| Humans | 32 | 2021 | 930598 | 0.12 | Why? |
| Health Care Costs | 1 | 2021 | 1007 | 0.12 | Why? |
| Emergencies | 2 | 2020 | 4095 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.11 | Why? |
| Government | 1 | 2021 | 1453 | 0.11 | Why? |
| Enterobacteriaceae Infections | 1 | 2017 | 529 | 0.11 | Why? |
| Continuous Positive Airway Pressure | 1 | 2020 | 1187 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.11 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.11 | Why? |
| Cost-Benefit Analysis | 1 | 2021 | 2259 | 0.11 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.11 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.11 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.11 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.11 | Why? |
| Rats | 1 | 2018 | 2764 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.10 | Why? |
| Oropharynx | 1 | 2017 | 1581 | 0.09 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.09 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.09 | Why? |
| Aspirin | 1 | 2016 | 1043 | 0.09 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.09 | Why? |
| Quality Improvement | 1 | 2021 | 2435 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2016 | 2886 | 0.09 | Why? |
| Algorithms | 3 | 2020 | 7346 | 0.09 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.09 | Why? |
| Drug Combinations | 1 | 2016 | 3852 | 0.08 | Why? |
| Adult | 8 | 2020 | 244371 | 0.08 | Why? |
| Aged | 8 | 2021 | 215776 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.08 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.07 | Why? |
| Male | 10 | 2021 | 367725 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.07 | Why? |
| Female | 10 | 2021 | 380317 | 0.07 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.07 | Why? |
| Latin America | 2 | 2021 | 1721 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.07 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.07 | Why? |
| Europe | 1 | 2021 | 12702 | 0.07 | Why? |
| Critical Illness | 2 | 2017 | 17281 | 0.06 | Why? |
| Ofloxacin | 1 | 2002 | 23 | 0.06 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Rheumatic Heart Disease | 1 | 2002 | 44 | 0.06 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.06 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 170 | 0.06 | Why? |
| Middle Aged | 7 | 2020 | 270681 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Aortic Valve Insufficiency | 1 | 2002 | 136 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.05 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Emergency Medical Services | 1 | 2017 | 3557 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.05 | Why? |
| Child | 2 | 2020 | 70012 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.05 | Why? |
| Mitral Valve Insufficiency | 1 | 2002 | 302 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2020 | 320 | 0.04 | Why? |
| Substance Abuse, Intravenous | 1 | 2002 | 411 | 0.04 | Why? |
| Mouth | 1 | 2002 | 622 | 0.04 | Why? |
| Colony Count, Microbial | 1 | 2017 | 177 | 0.04 | Why? |
| Infant | 1 | 2020 | 30274 | 0.04 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.04 | Why? |
| Intraabdominal Infections | 1 | 2017 | 90 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.04 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.04 | Why? |
| HIV Infections | 2 | 2017 | 11620 | 0.04 | Why? |
| Drug Resistance | 1 | 2018 | 395 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2002 | 1115 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.03 | Why? |
| Catheter-Related Infections | 1 | 2017 | 381 | 0.03 | Why? |
| Delphi Technique | 1 | 2017 | 1257 | 0.03 | Why? |
| Retrospective Studies | 3 | 2019 | 105322 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Platelet Count | 1 | 2017 | 1381 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Waste Water | 1 | 2021 | 2185 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.03 | Why? |
| Sex Factors | 2 | 2017 | 11014 | 0.03 | Why? |
| Inflammation | 1 | 2013 | 13255 | 0.03 | Why? |
| Clinical Protocols | 1 | 2021 | 2734 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2002 | 4002 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Vascular Diseases | 1 | 2017 | 846 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2002 | 7268 | 0.02 | Why? |
| Renal Replacement Therapy | 1 | 2017 | 1530 | 0.02 | Why? |
| Animals | 1 | 2018 | 78931 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.01 | Why? |
| Liver Transplantation | 1 | 2017 | 2864 | 0.01 | Why? |
| Risk Factors | 2 | 2017 | 71621 | 0.01 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2013 | 15421 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Candel's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(186)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(97)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_